Back to School: How biopharma can reboot drug development. Access exclusive analysis here
IVT will record a loss of $835,000 on the sale, but will be able to pledge its Enviromed shares
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury